Broad consideration of socio-economic factors when setting prices for a first-line heart disease medicine in multiple priority countries*
AstraZeneca considers five socio-economic factors when setting prices for a first-line heart disease medicine and targets 27% of priority countries. This is comparatively broad as the industry considers only two socio-economic factors per strategy, on average.
AstraZeneca has developed an internal governance structure for its Healthy Heart Africa programme, consisting of a Global Advisory Board and National Steering Committee.
AstraZeneca has a new pricing policy for its respiratory and cardiovascular disease products in certain key out-of-pocket markets in scope, based on an ability-to-pay analysis.
AstraZeneca, GSK and Merck KGaA publicly disclose their patent filing and enforcement policy, and disclose or commit to disclose their patent status and licensing approach to support third party manufacture and/or supply of patented products.
Nine companies have committed to R&D for antimicrobial resistance (AMR), signing the Davos Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance.